“Businesses need to submit, and have fully validated, novel food authorisation applications by 31 March 2021. After this date, only products for which the FSA has a valid application will be allowed to remain on the market.”
- Foods Standards Agency (FSA), February 2020
Lines open from 10am-6pm. By calling this number you agree to the terms of our privacy policy.
Contact us to become a member.
The key benchmarks for this are how many people express confidence in the efficacy of our products, and how many would be more likely to do so if there was better regulation.
In that context, the findings from our YouGov survey* are truly illuminating: they are a vindication of why we set up the ACI, launched the ACI charter and committed our members to working towards full novel foods authorisation and standardisation of analytical testing methodologies.
* Methodology: This survey has been conducted using an online interview administered to members of the YouGov Plc UK panel of 800,000+ individuals who have agreed to take part in surveys. Read More
20 May, 2020
The ACI have received clarification from the FSA on several points concerning novel foods dossier applications that have been raised by our members.
14 May, 2020
The ACI announces high-level discussions with the Laboratory of Government Chemists (LGC) that will focus on the development of a cannabinoid testing methodology with a higher precision control, an essential step towards standardisation for the industry.
12 May, 2020
2pm BST, Wednesday 27 May 2020
With the new novel foods regulation deadline looming this event will provide a unique opportunity to listen and engage with representatives of the UK’s regulator the Foods Standards Agency as well as industry experts from trading standards, toxicology, and the analytical testing and legal worlds.
28 May, 2020
THE ACI have received clarification from the Food Standards Agency regarding updated deadlines set for Cannabinoid firms to apply for Novel Foods.
21 May, 2020
The FSA clarified that several products may fall within the scope of a single CBD Novel Foods application, meaning that the finished product must be made with the applied for substance, for example, a CBD extract made by ‘X’ manufacturer, and that ‘the end use or presentation of the finished products is within the ‘uses’ identified by the application’, such as 5% CBD extract in oil.
21 May, 2020
Members from the Association for the Cannabinoid Industry (ACI) recently raised questions regarding CBD novel food dossier applications in the UK, and the FSA has now responded to their questions in a Q&A.
Lines open from 10am-6pm. By calling this number you agree to the terms of our privacy policy.
For media enquiries call +44 (0)7870515025
To find out more about membership, fill in the form below and our team will get back to you soon.